A Randomized, Open-label, Phase 3 Study in Subjects With Relapsed and Refractory Multiple Myeloma Receiving Carfilzomib in Combination With Dexamethasone, Comparing Once-weekly Versus Twice-weekly Carfilzomib Dosing

Trial Profile

A Randomized, Open-label, Phase 3 Study in Subjects With Relapsed and Refractory Multiple Myeloma Receiving Carfilzomib in Combination With Dexamethasone, Comparing Once-weekly Versus Twice-weekly Carfilzomib Dosing

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 11 Nov 2017

At a glance

  • Drugs Carfilzomib (Primary) ; Carfilzomib (Primary) ; Dexamethasone; Dexamethasone
  • Indications Multiple myeloma
  • Focus Registrational; Therapeutic Use
  • Acronyms A.R.R.O.W.; ARROW
  • Sponsors Amgen; Ono Pharmaceutical; Onyx Pharmaceuticals
  • Most Recent Events

    • 03 Nov 2017 Planned End Date changed from 1 Dec 2019 to 31 Dec 2018.
    • 23 Oct 2017 Top-line results presented in an Amgen media release.
    • 23 Oct 2017 Primary endpoint (Progression-free survival) has been met, according to an Amgen media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top